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OBJECTIVE: To develop a model characterizing the phenomena
of opioid rotation for chronic non-cancer pain. METHODS:
Literature review, supplemented by a panel of two pain special-
ists and one oncologist completed a questionnaire to provide
guidance on the typical treatment pathway of care for patients
requiring chronic long acting opioids for chronic non-cancer
pain. Guidance included management of commonly reported side
effects, frequency of follow up, dose adjustment and switch cri-
teria. RESULTS: A model reﬂecting three treatment arms was
constructed based on feedback from the panel: 1) MS Contin ER
switch to OPANA ER; 2) MS Contin ER switch to OxyContin
ER; 3) and OPANA ER switch to OxyContin ER for patients
where morphine is not an appropriate ﬁrst line treatment option.
Clinicians will evaluate the effectiveness and safety within 7–14
days to determine the need for drug switch or dose adjustment. If
a dose adjustment or medication switch is required, further
follow up within 7–14 days will take place. Most patients’ pain
is likely to be controlled with tolerable side effects within the ﬁrst
28–42 days of initiation of therapy. For patients not controlled,
dose adjustment, switching or consultation with a pain specialist
may be required. Over the course of one year, up to 50 different
pathways were possible for each treatment arm which may
include two or more different opioids and up to ﬁve dose
adjustments. CONCLUSION: Opioid rotation is not well char-
acterized. Switching medications, adjusting dose and frequent
follow-up, contribute to incremental costs. Appropriate selection
of second or third line therapy should include consideration for
patient tolerability. Further analysis from a long-term registry
currently underway may provide further guidance for validating
the proposed model in order to better evaluate the cost impact of
switching, frequency of physician contacts, and dose adjustments
associated with opioid rotation.
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OBJECTIVE: To understand the relationship between morbidly
obese patients’ reasons for ofﬁce visits, physicians’ diagnoses of
obesity, and obesity treatments, using a patient ﬂow model.
METHODS: We used the 2005 National Ambulatory Medical
Care Survey, a nationally representative survey of visits to non-
federal ofﬁce-based physicians, including specialists. Patients
with body mass index (BMI) >=40 were categorized as morbidly
obese, based on ofﬁce-recorded height and weight. We created a
patient ﬂow model to study obesity diagnosis rates based on
patients’ stated reasons for visit, and obesity treatment rates
based on type of diagnosis. Reported percentages are based on
weighted frequency counts. RESULTS: In 2005, there were 962.7
million ofﬁce visits by non-pregnant adults (>=18 yrs) of which
38.7% had both height and weight recorded. Of these, 24.1
million (6.5%) visits were made by morbidly obese patients. Less
than 5% stated weight gain as a reason for visit. The rate of
physician diagnosis of obesity was 12.0%, with an additional
38.6% noted (but not diagnosed) as obese, leaving 49.4%
neither diagnosed nor noted as obese. Obesity diagnosis rates
greatly improved when patients stated weight gain as a reason for
visit (81.5%). Overall only 2.1% received an obesity prescrip-
tion, 38.7% received health education for weight reduction, diet/
nutrition or exercise, and 59.2% received none of the above.
Treatment rates improved signiﬁcantly with an obesity diagnosis,
with 4.2% receiving an obesity prescription and 80.1% receiving
health education. CONCLUSION: Among morbidly obese
patients, the rate of physician diagnosis and treatment is very
low. However, rates improve when patients state weight gain as
a concern. These patient ﬂows clearly demonstrate that both the
patient and physician have a shared responsibility in addressing
the condition and efforts are needed to further involve both
stakeholders in tackling the obesity epidemic.
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OBJECTIVE: A systematic review is the preferred approach for
assembling clinical evidence. The gold standard for literature
searching comprises sensitive search strategies applied to mul-
tiple literature databases and hand-searching of journals and
conference abstracts. As a follow-up to a previous ISPOR poster,
we sought to evaluate the impact of different search approaches
on the pooled statistical results from systematic reviews, rather
than simply numbers of studies included. METHODS: Previ-
ously, we selected a series of published Cochrane systematic
reviews and compared the effect of more limited search strategies
(a search of multiple literature databases without grey literature,
and a Medline keyword search) on the number of included
studies. We extended this work to compare the pooled effect sizes
resulting from meta-analyses of key outcomes from the studies
included in each search strategy. The reviews covered ﬁve differ-
ent areas: smoking cessation, non-small cell lung cancer, neuro-
pathic pain, acupuncture and Crohn’s disease. All meta-analyses
where studies were missed by lower level searches were re-run
including only the studies retrieved by these searches. This
allowed the impact of missing studies on the meta-analysis result
to be assessed. RESULTS: Differences between meta-analysis
results were generally fairly minimal, although in some cases
missing studies changed the result of a meta-analysis from a
signiﬁcant to a non-signiﬁcant result. In several cases lower level
searches resulted in there being no studies at all looking at
particular outcomes. For example, in a review of neuropathic
pain treatments, which showed a signiﬁcant effect of antidepres-
sants versus placebo on atypical facial pain relief (RR = 1.67),
both studies included in the meta-analysis were absent when
searching with a Medline keyword search only. CONCLU-
SIONS: A comprehensive search strategy is needed to retrieve all
relevant studies in a systematic review. Less comprehensive
searches impact results of meta-analyses and can distort the
evidence base.
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WHEN ARE INDIRECT AND MIXEDTREATMENT
COMPARISONS BIASED? A GRAPHICAL EXPLANATION
WITH DAGS
Jansen JP
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In the absence of head-to-head randomized studies, often indirect
treatment comparisons are performed for reimbursement sub-
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